RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 ODYSSEY FH I and FH II: Alirocumab Significantly Improves Cholesterol Levels in Patients with HeFH
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 27
SP 18
OP 19
DO 10.1177/155989771427012
UL http://mdc.sagepub.com/content/14/27/18.abstract
AB This article presents results from the Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy trial [ODYSSEY FH I; NCT01623115] and the Study of Alirocumab (REGN727/ SAR236553) in Patients With HeFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) trial [ODYSSEY FH II; NCT01709500].